Another Humira Biosimilar Debuts In India
This article was originally published in Scrip
Executive Summary
A second biosimilar version of AbbVie's blockbuster biologic, Humira (adalimumab), has made its debut in India, with Torrent Pharma following Zydus Cadila onto the domestic market with its version.
You may also be interested in...
Hetero Set To Join Indian Humira Biosimilar Line-Up
Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.
Hetero Set To Join Indian Humira Biosimilar Line-Up
Hetero’s biosimilar version of AbbVie's Humira (adalimumab) appears on course to a debut in India and is set to follow peers like Zydus Cadila and Torrent, signaling the build-up of more competition for the blockbuster biologic across markets.
Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China
Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.